8-KRegulation FD

ABBOTT LABORATORIES 8-K Report, Regulation FD Disclosure (Aug 31, 2005)

Filed August 31, 2005For Securities:ABT

Summary

This 8-K filing from Abbott Laboratories, dated August 31, 2005, announces an amendment to its U.S. co-promotion agreement with MedImmune, Inc. concerning the product Synagis®. The amendment extends Abbott's co-promotion activities for Synagis® in the United States through June 30, 2006, and continues milestone payments based on U.S. sales performance until March 30, 2007. This adjustment primarily impacts Abbott's revenue streams and promotional responsibilities for a key product. Investors should note that the international co-promotion agreements for Synagis® and the development product Numax™ remain unaffected. The filing is made under Regulation FD and is furnished, not filed, meaning it's for disclosure purposes and not automatically incorporated into other SEC filings.

Key Highlights

  • 1Abbott Laboratories amended its U.S. co-promotion agreement for Synagis® with MedImmune, Inc.
  • 2Abbott will continue Synagis® co-promotion activities in the U.S. through June 30, 2006.
  • 3Milestone payments for Abbott related to U.S. Synagis® sales will continue through March 30, 2007.
  • 4International co-promotion agreements for Synagis® and Numax™ are unchanged.
  • 5The amendment is stated to be for the mutual benefit of both Abbott and MedImmune.
  • 6This disclosure is being made under Regulation FD and is furnished, not filed.

Frequently Asked Questions

The main purpose of this 8-K filing is to disclose an amendment to Abbott Laboratories' co-promotion agreement with MedImmune, Inc. regarding the product Synagis® in the United States. This amendment modifies the duration of Abbott's promotional services and the period for receiving milestone payments based on U.S. sales.

Abbott will continue its co-promotion efforts for Synagis® in the U.S. until June 30, 2006, and will receive milestone payments tied to U.S. sales performance through March 30, 2007. This indicates an extended, albeit modified, commercial relationship for this product in the U.S. market.

No, the filing explicitly states that the international co-promotion agreements for Synagis® and Numax™ remain unchanged by this U.S. contract amendment. The changes are specific to the U.S. market.

Numax™ is MedImmune's next-generation anti-RSV antibody, currently in Phase III development. While not directly impacted by this U.S. amendment, its mention highlights Abbott's ongoing international collaboration with MedImmune on potential future products.